within Pharmacolibrary.Drugs.ATC.D;

model D10AA03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.81,
    Cl             = 2.111111111111111e-06,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,
    adminCount     = 1,
    Vd             = 0.065,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600,            
    Vdp             = 0.105,
    k12             = 1.916666666666667e-06,
    k21             = 1.916666666666667e-06
    
  );
  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dexamethasone</td></tr><tr><td>ATC code:</td><td>D10AA03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>65</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressant properties. It is widely used to treat conditions such as allergies, skin diseases, rheumatoid disorders, shock, cerebral edema, and as part of some cancer therapies. Dexamethasone is approved and commonly used globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adults after oral administration. Data is derived from clinical pharmacokinetic studies in volunteers.</p><h4>References</h4><ol><li><p>Wen, J, et al., &amp; Gonzalez, D (2024). Pharmacokinetics of Dexamethasone in Children and Adolescents with Obesity. <i>Journal of clinical pharmacology</i> 64(12) 1491–1504. DOI:<a href=\"https://doi.org/10.1002/jcph.6108\">10.1002/jcph.6108</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39120865/\">https://pubmed.ncbi.nlm.nih.gov/39120865</a></p></li><li><p>Wang, X, et al., &amp; Kansra, V (2019). Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting. <i>Clinical pharmacology in drug development</i> 8(7) 850–860. DOI:<a href=\"https://doi.org/10.1002/cpdd.733\">10.1002/cpdd.733</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31418538/\">https://pubmed.ncbi.nlm.nih.gov/31418538</a></p></li><li><p>Nakade, S, et al., &amp; Miyata, Y (2008). Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. <i>Cancer chemotherapy and pharmacology</i> 63(1) 75–83. DOI:<a href=\"https://doi.org/10.1007/s00280-008-0713-y\">10.1007/s00280-008-0713-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18317761/\">https://pubmed.ncbi.nlm.nih.gov/18317761</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end D10AA03;
